Industry updates with Dusko Ilic: March 2019
Read highlights from the latest instalment of Dusko Ilic’s industry updates, which discuss the latest developments and news in regenerative medicine and stem cell research, and are published every month in Regenerative Medicine.
Every month, Dusko comments on news of note. Read the full update for March 2019 on Regenerative Medicine here>>
1. What happened this month that you were expecting?
It was about time that Japan has relaxed its human-animal chimeric embryo research regulations.
2. What happened that surprised you this month?
In spite of looming Brexit and a dire prognosis for the British economy, TCR² Therapeutics (MA, USA) have announced a collaboration with the Cell and Gene Therapy Catapult (London, UK) for the manufacture of its novel T cell therapies for cancer. This is the first US company to choose the Stevenage, UK site as its global production development base.
3. If we only read about one story this month, what should it be?
Harvard has licensed its immune-silent stem cell technology to Sana Biotechnology. In addition to the platform technology, which is exclusively licensed to Sana within the field of therapeutics, the license agreement grants Sana non-exclusive access to Harvard technology for performing high-efficiency, ex vivo genome editing.
Read the full industry update for March 2019>>
Dusko Ilic is a Senior Lecturer in stem cell science, coordinator of the cross-divisional postgraduate program in stem cells and regenerative medicine, and Head of the Induced Pluripotent Stem Cell Core Facility at King’s College London (London, UK). He is also Head of the Assisted Conception Unit’s Human Embryonic Laboratories at Guy’s Hospital (London, UK). He is also a member of the editorial board of the journal Regenerative Medicine, where he writes the Industry Report, a regular feature compiling information from non-academic institutions in the field of stem cells and regenerative medicine.
